Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERSEPHONE trastuzumab duration trial
ISRCTN52968807Phase 3Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Oct 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of trastuzumab in breast cancer (2 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Disease-free survival. Started Oct 2007; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN52968807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN52968807.